@article{d1fb18dfe14e479d93baa4693b7fa78e,
title = "Tryptophan depletion and emotional processing in healthy volunteers at high risk for depression",
abstract = "Background: Studies in depressed patients have demonstrated the presence of emotional bias toward negative stimuli, as well as dysregulated brain serotonin function. The present study compared the effects of acute tryptophan depletion (ATD) on both an emotional processing and a planning task in never-depressed healthy volunteers at high and low familial risk for depression. Methods: Young adults with no personal psychiatric history were stratified into two groups based on family history (n = 25). Participants were enrolled in a randomized, double-blind, placebo-controlled crossover ATD study and completed the affective go/no-go and Tower of London tasks once during each condition. Results: There was a significant treatment by valence by group interaction on the affective go/no-go, driven primarily by a greater frequency of inappropriate responses to sad than to happy distracters in the high-risk group during ATD. No group differences were observed on the Tower of London. Conclusions: Asymptomatic individuals at high familial risk for depression showed abnormalities in emotional processing while undergoing experimentally induced tryptophan depletion. These findings support emotional processing disturbances as potential trait-level abnormalities associated with the risk of mood disorder.",
keywords = "Affective go/no-go, emotional processing, family history, high risk, major depression, tryptophan depletion",
author = "Adriana Feder and Jamie Skipper and Blair, {James R.} and Katherine Buchholz and Mathew, {Sanjay J.} and Markus Schwarz and Doucette, {John T.} and Angelique Alonso and Collins, {Katherine A.} and Alexander Neumeister and Charney, {Dennis S.}",
note = "Funding Information: Dr. Feder has received grant/research support from GlaxoSmithKline . Dr. Mathew has received grant/research support from Alexza Pharmaceuticals , GlaxoSmithKline , Novartis , National Alliance for Research on Schizophrenia and Depression , and Roche and has received consulting or lecture fees from AstraZeneca, Evotec Jazz Pharmaceuticals, Merck, and Pfizer. Dr. Neumeister has received grant/research support from Pfizer, Inc. ; Eli Lilly ; UCB Pharma, Inc. ; and Ortho-McNeil Janssen Scientific Affairs, LLC . In addition, Drs. Charney and Mathew have been named as inventors on a use-patent of ketamine for the treatment of depression. Dr. Charney reported no other biomedical financial interests or potential conflicts of interest. Ms. Skipper, Dr. Blair, Ms. Buchholz, Dr. Schwarz, Dr. Doucette, Ms. Alonso, and Ms. Collins reported no biomedical financial interests or potential conflicts of interest. Funding Information: This work was performed at the Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, and was funded by Grant Number MO1-RR00071 from the National Center for Research Resources , a component of the National Institutes of Health. ",
year = "2011",
month = apr,
day = "15",
doi = "10.1016/j.biopsych.2010.12.033",
language = "English (US)",
volume = "69",
pages = "804--807",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "8",
}